PPARA and metabolic dysfunction-associated steatotic liver disease: Saroglitazar, a dual PPAR α/γ agonist, has achieved a promising effect in the treatment of NAFLD in a phase 2 study(NCT03061721) (Gawrieh et al., 2021).